gist
No description yet: the sentence for this tag has not been written. 5 records carry it: 4 people, 1 biomarker.
Related tags
By kind
5 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
George D. Demetri Director, Sarcoma Center and Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute; Professor, Harvard Medical School · Dana-Farber Brigham Cancer Center Led the imatinib trial in GIST that proved a targeted drug could melt away a solid tumour, and every GIST kinase inhibitor since. | Gastrointestinal stromal tumour, Sarcomas | none | sarcoma, targeted-therapy | ||
Heikki Joensuu Professor of Oncology, Helsinki University Hospital · HUS Comprehensive Cancer Center, Helsinki University Hospital Finnish oncologist who treated the first GIST patient with imatinib in 2000 and led SSG XVIII, the trial that showed three years of adjuvant imatinib beats one year after surgery for high-risk GIST. | KIT exon 11-mutant GIST, Gastrointestinal stromal tumour, Sarcomas | none | trialist | ||
Michael C. Heinrich Medical oncologist and laboratory scientist, Oregon Health & Science University and Portland VA · OHSU Knight Cancer Institute Oregon physician-scientist who showed that the KIT mutation type in a GIST predicts how well imatinib works, discovered PDGFRA mutations in the tumours without KIT mutations, and led NAVIGATOR, which established avapritinib for PDGFRA D842V disease. | PDGFRA D842V-mutant GIST, KIT exon 11-mutant GIST, Gastrointestinal stromal tumour | none | targeted-therapy, trialist | ||
PDGFRA exon 18 mutation (D842V) PDGFRA PDGFRA D842V drives about 5 percent of gastrointestinal stromal tumours and is resistant to imatinib. Avapritinib is the approved drug for GISTs with PDGFRA exon 18 mutations including D842V. | Gastrointestinal stromal tumour, PDGFRA D842V-mutant GIST | none | biomarker | ||
Sebastian Bauer Medical oncologist, West German Cancer Center, University Hospital Essen · West German Cancer Center (WTZ), University Hospital Essen German sarcoma specialist who was lead author of INTRIGUE, the trial that compared ripretinib with sunitinib as second-line treatment for GIST. | Imatinib-resistant GIST, Gastrointestinal stromal tumour, Sarcomas | none | sarcoma, trialist |